WO2022124410A1 - シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 - Google Patents
シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 Download PDFInfo
- Publication number
- WO2022124410A1 WO2022124410A1 PCT/JP2021/045679 JP2021045679W WO2022124410A1 WO 2022124410 A1 WO2022124410 A1 WO 2022124410A1 JP 2021045679 W JP2021045679 W JP 2021045679W WO 2022124410 A1 WO2022124410 A1 WO 2022124410A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- group
- cytosine
- nucleoside amidite
- solvent
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 119
- 239000002777 nucleoside Substances 0.000 title claims abstract description 92
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims abstract description 87
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- -1 dimethylaminomethylene Chemical group 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 26
- 150000002825 nitriles Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 230000001012 protector Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 11
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 11
- 238000000113 differential scanning calorimetry Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000013112 stability test Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ASOJEESZSWWNQK-RRKCRQDMSA-N 5-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O ASOJEESZSWWNQK-RRKCRQDMSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- IDNJBJJSMDYULP-UHFFFAOYSA-N chlorophosphonamidous acid Chemical compound NP(O)Cl IDNJBJJSMDYULP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a cytosine-type crosslinked nucleoside amidite crystal and a method for producing the same.
- antisense method antigene method, aptamer method, siRNA method, etc. as a treatment method for diseases by nucleic acid medicine.
- the furanose ring of the nucleoside sugar moiety has a distorted conformation called N-type or S-type rather than a planar structure, and is biased to a specific conformation by a cyclic substituent.
- N-type conformation becomes dominant. Imanishi et al. Succeeded in forcibly fixing the conformation of the nucleoside to the N-type by cross-linking the 4'-position and 2'-position hydroxyl groups of the nucleoside sugar moiety.
- LNA Locked Nucleic Acids
- LNA is generally synthesized by a solid-phase synthesis method using a crosslinked nucleoside amidite, which is called a phosphoramidite method (see Non-Patent Document 1).
- LNA is synthesized by repeating the cycle of detritylation ⁇ coupling reaction of amidite compound ⁇ cap reaction ⁇ oxidation (or Sification) reaction until the target chain length is reached. That is, the amidite form of the crosslinked nucleoside is industrially useful because it is used as a raw material for LNA synthesis.
- the present inventor has found that the amorphous stability of the amidite form of the crosslinked nucleoside is low while examining the synthesis of LNA.
- An object of the present invention is to solve the above-mentioned amorphous problem existing in the amidite form of a crosslinked nucleoside.
- the present inventor acquired the crystals of the amidite form of the cytosine-type cross-linked nucleoside for the first time while proceeding with diligent research. Then, it was found that the crystal could solve the above-mentioned problem of amorphous, and further studies were carried out to complete the present invention.
- the cytosine-type cross-linked nucleoside amidite is referred to as "cytosine-type cross-linked nucleoside amidite”
- the crystal thereof is referred to as “cytosine-type cross-linked nucleoside amidite crystal”
- the amorphous cytosine-type cross-linked nucleoside amidite is referred to as "cytosine-type cross-linked nucleoside amidite”. It may be abbreviated as "cytosine type cross-linked nucleoside amidite amorphous”.
- the present invention is a cytosine-type crosslinked nucleoside amidite crystal represented by the following structural formula.
- R 1 and R 2 indicate a substituent
- R 3 indicates a protecting group
- the present invention is a method for producing a cytosine-type cross-linked nucleoside amidite crystal, which comprises a step of dissolving a cytosine-type cross-linked nucleoside amidite amorphous substance in a nitrile-based solvent to obtain a precipitated crystal.
- the present invention is a method for producing a cytosine-type cross-linked nucleoside amidite crystal, which comprises a step of dissolving a cytosine-type cross-linked nucleoside amidite amorphous in an easily soluble solvent and then adding a sparingly soluble solvent.
- the present invention it is possible to provide a cytosine-type crosslinked nucleoside amidite crystal and a method for producing the same, which solves the above-mentioned amorphous problem existing in the amidite form of the crosslinked nucleoside. That is, the cytosine-type crosslinked nucleoside amidite crystal of the present invention has excellent stability and can be stably stored even under a high temperature condition of 50 ° C.
- FIG. 1 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 1.
- the appearance of the crystal A of —O— [O— (2-cyanoethyl) -N, N-diisopropylphosphoroamidite] is shown.
- FIG. 2 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 2.
- FIG. 3 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 3.
- the appearance of the crystal C of —O— [O— (2-cyanoethyl) -N, N-diisopropylphosphoroamidite] is shown.
- Example 4 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 1.
- the X-ray diffraction spectrum of the crystal A of -O- [O- (2-cyanoethyl) -N, N-diisopropylphosphoroamidite] is shown.
- the vertical axis represents the diffraction intensity (CPS), and the horizontal axis represents the diffraction angle (2 ⁇ ).
- Example 5 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 2.
- the X-ray diffraction spectrum of the crystal B of -O- [O- (2-cyanoethyl) -N, N-diisopropylphosphoroamidite] is shown.
- the vertical axis represents the diffraction intensity (CPS), and the horizontal axis represents the diffraction angle (2 ⁇ ).
- Example 7 shows N 4 -benzoyl-5'-O- (4,4'-dimethoxytrityl) -2'-O-4'-C-methylene-5-methylcytidine-3'acquired in Example 1.
- the results of differential scanning calorimetry of crystal A of -O- [O- (2-cyanoethyl) -N, N-diisopropylphosphoroamidite] are shown.
- “DSC mW" on the vertical axis represents a change in calorific value
- Temp ° C on the horizontal axis represents a change in temperature.
- the present invention provides, in one embodiment, a cytosine-type crosslinked nucleoside amidite crystal represented by the following structural formula.
- R 1 and R 2 indicate a substituent
- R 3 indicates a protecting group.
- the substituent represented by R 1 is an amino group or an amino group protected by an acyl group such as an acetyl group, a propionyl group, an isobutyryl group or a benzoyl group or a dimethylaminomethylene group.
- the substituent represented by R 2 is a methyl group or a hydrogen atom.
- the protecting group represented by R 3 is a trityl group, a monomethoxytrityl group, a dimethoxytrityl group or a pixyl group.
- R 1 is preferably a benzamide group
- R 2 is preferably a methyl group
- R 3 is preferably a dimethoxytrityl group.
- the cytosine-type crosslinked nucleoside amidite crystal of the present invention can take different crystal forms depending on the difference in crystal acquisition conditions.
- this polymorph is referred to as crystal A, crystal B and crystal C for convenience.
- the cytosine-type crosslinked nucleoside amidite crystal of the present invention is obtained as a columnar or dendritic crystal.
- a photograph of the appearance of the crystal A is shown in FIG. 1
- a photograph of the appearance of the crystal B is shown in FIG. 2
- a photograph of the appearance of the crystal C is shown in FIG.
- crystals A and B having a diffraction angle (2 ⁇ ) shown below are shown below.
- crystals A and B having a diffraction angle (2 ⁇ ) shown below are shown below.
- crystal C Crystal A 7.96, 8.94, 9.50, 10.49, 11.000, 11.12, 13.45, 13.82, 16.79, 17.76, 18.22, 19.
- the diffraction angle (2 ⁇ ) in powder X-ray diffraction may include an error range of less than 5%. Therefore, in addition to crystals in which the peak diffraction angles in powder X-ray diffraction completely match, the peak diffraction angle Crystals with an error of less than 5% are also included in the cytosine-type crosslinked nucleoside amidite crystals of the present invention.
- the cytosine-type crosslinked nucleoside amidite crystal of the present invention has one of the characteristic peak patterns of crystal A, crystal B, and crystal C shown below as the diffraction angle (2 ⁇ ) of powder X-ray diffraction. Have.
- powder X-ray diffraction shall be performed under the following conditions.
- the citocin-type crosslinked nucleoside amidite crystal of the present invention was analyzed by a differential scanning calorimeter (manufactured by Shimadzu Corporation) (heating rate 5 ° C./min), the crystal A had 96, 176, as shown in FIG. Near 184 ° C (error of ⁇ 2 ° C), around 148 and 183 ° C (error of ⁇ 2 ° C) as shown in FIG. 8 for crystal B, and around 177 and 183 ° C ( ⁇ 2) as shown in FIG. 9 for crystal C.
- the heat absorption peak due to melting is shown in (° C error).
- no endothermic peak was shown as shown in FIG.
- the cytosine-type crosslinked nucleoside amidite crystal of the present invention has extremely high stability, and as demonstrated in Examples described later, it decomposes even when stored for 20 days under the condition of, for example, 50 ° C. The degree can be suppressed to within 1%.
- the "decomposition degree” is the purity after storage from the purity of the cytosine-type crosslinked nucleoside amidite crystal at the start of the stability test when the stability test is performed for a certain period under the following conditions. Defined as subtracted. Purity can be determined by HPLC. A large degree of decomposition means that the decomposition has progressed and the purity has decreased.
- Stability test conditions Temperature: 50 ° C Storage conditions: 20 mg of crystals in a glass vial and sealed storage (HPLC conditions) Column: YMC-Triart C18, 150 ⁇ 4.6 mm I. D. (Made by YMC) Eluent: 5 mM triethylammonium acetate (pH 7.0) containing 80% by volume acetonitrile Detection method: Detection by UV280 nm
- the present invention provides, in another embodiment, a method for producing a cytosine-type crosslinked nucleoside amidite crystal.
- the cytosine-type crosslinked nucleoside amidite crystal of the present invention can be obtained by utilizing the low affinity of the phosphoramidite group for a nitrile-based solvent. That is, the cytosine-type crosslinked nucleoside amidite crystal of the present invention can be obtained by dissolving the cytosine-type crosslinked nucleoside amidite amorphous in a nitrile-based solvent and precipitating the crystals (method A). Alternatively, as another method, cytosine-type crosslinked nucleoside amidite crystals can be obtained by dissolving cytosine-type crosslinked nucleoside amidite amorphous in an easily soluble solvent and then adding a sparingly soluble solvent (method B).
- Method A As a specific method of Method A, after the addition reaction of the phosphoramidite group shown in Chemical formula 3 below and a normal purification operation, the obtained cytosine-type crosslinked nucleoside amidite amorphous substance is once dissolved in a nitrile solvent. Then, a method of precipitating as crystals is exemplified. At this time, operations such as stirring and cooling are not particularly required, but these operations may be performed.
- R 1 and R 2 indicate a substituent
- R 3 indicates a protecting group
- acetonitrile, propionitrile, butyronitrile, valeronitrile, benzonitrile and the like can be used as the nitrile-based solvent.
- acetonitrile and propionitrile are preferable from the viewpoint of safety and handling, and acetonitrile is more preferable from the viewpoint of cost.
- a protic protic solvent such as methanol or ethanol
- a non-polar solvent such as dichloromethane, ethyl acetate, chloroform or tetrahydrofuran because the compound has high solubility. ..
- a cytosine-type crosslinked nucleoside amidite amorphous obtained in the same manner as in the method A is once dissolved in an easily soluble solvent and then precipitated as crystals by adding a poorly soluble solvent.
- the easily soluble solvent include alcohol solvents such as methanol, ethanol, isopropanol, tert-butanol and n-butanol, ketone solvents such as acetone and butanone, halogen solvents such as dichloromethane and chloroform, ethyl acetate and butyl acetate.
- ester-based solvents ether-based solvents such as tetrahydrofuran and tert-butylmethyl ether can be used.
- a hydrocarbon solvent such as pentane, hexane, or heptane can be used.
- This synthesis step can be performed by those skilled in the art by appropriately referring to known documents (Tetrahedron 1998, 54, 3607-3630, etc.). Examples include combinations of 2-cyanoethyl-N, N, N', N'-tetraisopropylphosphoroamidite with tetrazole or substituted tetrazole in organic solvents such as acetonitrile or dichloromethane, or 2-cyanoethyl-N, N-diisopropyl.
- a combination of chlorophosphoroamidite and diisopropylethylamine may be reacted at room temperature for 2 to 3 hours, and after confirming the disappearance of the raw material by thin layer chromatography (TLC) or HPLC, normal post-treatment may be performed.
- TLC thin layer chromatography
- HPLC HPLC
- the cytosine-type crosslinked nucleoside amidite synthesized in this manner is purified by chromatography using silica gel or the like as a carrier and then dissolved in a nitrile-based solvent. It can be precipitated as crystals by adding operations such as addition, cooling, and stirring.
- the cytosine-type crosslinked nucleoside amidite crystals obtained by the above production method can be made into a product by filtering by a filtration method such as pressure filtration, vacuum filtration, basket separation, filter press, and then drying.
- a filtration method such as pressure filtration, vacuum filtration, basket separation, filter press, and then drying.
- methods such as conical drying, vacuum drying including shelf drying, fluidized bed drying, ventilation drying including shelf drying, and spray drying can be appropriately used.
- R 1 benzamide group
- R 2 methyl group
- R 3 dimethoxytrityl group
- FIG. 2 shows an external photograph of the crystal B acquired in Example 2
- FIG. 3 shows an external photograph of the crystal C acquired in Example 3.
- the purity of the 5-methylcytosine-type cross-linked nucleoside nucleoside crystals B and C obtained in Examples 2 and 3 was measured under the same conditions, and the 5-methylcytosine-type cross-linking obtained in Example 2 was carried out.
- the purity of the type nucleoside amidite crystal B was 98.7%
- the purity of the 5-methylcytosine type crosslinked nucleoside amidite crystal C obtained in Example 3 was 98.6%.
- a characteristic peak was shown in the vicinity.
- a characteristic peak was shown in the vicinity.
- Example 5 Stability comparison between 5-methylcytosine-type cross-linked nucleoside amidite crystals and known amorphous crystals
- Example 1 (Crystal A)
- Example 2 the 5-methylcytosine-type crosslinked nucleoside amidite
- Example 2 Methyl group
- Example 3 Dimethoxytrityl group
- the HPLC purity of Crystal A after the corresponding number of days the column of “Example 2 (Crystal B)” is the 5-methylcytosine type cross-linking obtained in Example 2.
- Column shows the HPLC purity of the amorphous used as a control after the corresponding number of days.
- the cell described as "-" in the table indicates that the measurement has not been performed.
- the “decomposition degree ( ⁇ %)" at the bottom shows the difference when the HPLC purity after 20 days has passed from the HPLC purity on the 0th day, and the larger this value is, the more decomposition has occurred. ing.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
今西らは、ヌクレオシド糖部の4’位と2’位水酸基とを架橋することにより、ヌクレオシドのコンフォメーションを強制的にN型に固定することに成功した。結果として、この架橋型ヌクレオシドを含むLNA(Locked Nucleic Acids)は、相補的な配列の核酸と極めて安定な2重鎖を形成することが明らかとなった(特許文献1参照)。
上記の特性等から、近年、核酸医薬の素材として、LNAに対する期待が高まっている。
(結晶A)7.96,8.94,9.50,10.49,11.00,11.12,13.45,13.82,16.79,17.76,18.22,19.14,19.27,19.84,20.31,20.60,21.38,22.65,24.99,25.33,26.42(°)
(結晶B)8.09,10.28,10.59,11.07,11.38,12.93,13.50,15.01,16.73,16.92,17.43,17.74,18.77,19.71,20.51,21.50,21.74,22.00,22.22,22.72,23.43,23.80,24.13,24.78,28.10(°)
(結晶C)8.06,10.20,10.52,11.01,11.35,11.63,12.92,13.48,14.93,15.95,16.68,16.89,17.33,17.61,18.50,18.72,19.70,19.90,20.49,21.43,21.85,22.16,22.57,23.76,27.96(°)
結晶Aのピークパターンを図4に、結晶Bのピークパターンを図5に、結晶Cのピークパターンを図6に示す。
(結晶A)7.96±0.40,8.94±0.45,9.50±0.48,10.49±0.52,11.00±0.55,11.12±0.56,13.45±0.67,13.82±0.69,16.79±0.84,17.76±0.89,18.22±0.91,19.14±0.96,19.27±0.96,19.84±0.99,20.31±1.02,20.60±1.03,21.38±1.07,22.65±1.13,24.99±1.25,25.33±1.27,26.42±1.32(°)
(結晶B)8.09±0.41,10.28±0.51,10.59±0.53,11.07±0.55,11.38±0.57,12.93±0.65,13.50±0.68,15.01±0.75,16.73±0.84,16.92±0.85,17.43±0.87,17.74±0.89,18.77±0.94,19.71±0.99,20.51±1.03,21.50±1.08,21.74±1.09,22.00±1.10,22.22±1.11,22.72±1.14,23.43±1.17,23.80±1.19,24.13±1.21,24.78±1.24,28.10±1.41(°)
(結晶C)8.06±0.40,10.20±0.51,10.52±0.53,11.01±0.55,11.35±0.57,11.63±0.58,12.92±0.65,13.48±0.67,14.93±0.75,15.95±0.80,16.68±0.83,16.89±0.85,17.33±0.87,17.61±0.88,18.50±0.93,18.72±0.94,19.70±0.99,19.90±1.00,20.49±1.02,21.43±1.07,21.85±1.09,22.16±1.11,22.57±1.13,23.76±1.19,27.96±1.40(°)
使用機器:X線回折装置X’Pert PRO MPD(スペクトリス)
ターゲット:Cu
X線管電流:40mA
X線管電圧:45kV
走査範囲:2θ=4.0~40.0°
(安定性試験条件)
温度:50℃
保管条件:結晶をガラスバイアル中に20mg入れ密閉保管
(HPLC条件)
カラム:YMC-Triart C18,150×4.6mmI.D.(YMC社製)
溶出液:80体積%アセトニトリルを含む5mM トリエチルアンモニウムアセテート(pH7.0)
検出法:UV280nmによる検出
公知の文献(Tetrahedron 1998,54,3607-3630)に記載の方法に従い、5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)を調製した。
得られたアモルファス状の5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)0.65gを、アセトニトリル 5mLに溶解し、-20℃で7日間静置することで結晶が析出した。
公知の文献(Tetrahedron 1998,54,3607-3630)に記載の方法に従い、5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)を調製した。
得られたアモルファス状の5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)1.00gを、ジクロロメタン 1mLに溶解後、ヘキサン 15mLを徐々に添加した。この溶液に超音波を照射することで結晶が析出した。この溶液に、ヘキサンをさらに10mL添加後、3時間静置した。溶液中に析出した結晶を、吸引濾取後、真空乾燥することにより、5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)の結晶を取得した(0.81g)。
公知の文献(Tetrahedron 1998,54,3607-3630)に記載の方法に従い、5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)を調製した。
得られたアモルファス状の5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)1.00gを、アセトニトリル 1mLに溶解し、-20℃で2時間静置することで結晶が析出した(0.80g)。
実施例1に記載の方法でアモルファス状の5-メチルシトシン型架橋型ヌクレオシドアミダイトを取得した。溶解させる溶媒をアセトニトリルからジクロロメタンのみ、又はジクロロメタン-アセトニトリル(1:1)に替え、その他の条件は実施例1と同条件として結晶化検討を行ったが、結晶は析出しなかった。
実施例1,2,3にて取得された5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶の各種物性分析を行った。
実施例1にて取得された5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶Aの外観写真を図1に示す。図1に示すように、5-メチルシトシン型架橋型ヌクレオシドアミダイト結晶は柱状の結晶形を示すことが明らかとなった。
上記実施例1にて取得された5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶Aの純度を、HPLC法で分析した結果、5-メチルシトシン型架橋型ヌクレオシドアミダイト結晶Aの純度は98.8%であった。なお、HPLC法は以下の条件で行った。
(HPLC条件)
カラム:YMC-Triart C18,150×4.6mmI.D.(YMC社製)
溶出液:80体積%アセトニトリルを含む5mM トリエチルアンモニウムアセテート(pH7.0)
検出法:UV280nmによる検出
実施例1~3にて取得された5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶A、B及びCについて、X線回折装置X’Pert PRO MPD(スペクトリス)を用い、下記の測定条件でX線回折スペクトルを測定した。
(測定条件)
ターゲット:Cu
X線管電流:40mA
X線管電圧:45kV
走査範囲:2θ=4.0~40.0°
(結晶A)7.96,8.94,9.50,10.49,11.00,11.12,13.45,13.82,16.79,17.76,18.22,19.14,19.27,19.84,20.31,20.60,21.38,22.65,24.99,25.33,26.42(°)付近にピークを示し、特に7.96,11.00,13.45,13.82,16.79,17.76,20.60(°)
付近に特徴的なピークを示した。
(結晶B)8.09,10.28,10.59,11.07,11.38,12.93,13.50,15.01,16.73,16.92,17.43,17.74,18.77,19.71,20.51,21.50,21.74,22.00,22.22,22.72,23.43,23.80,24.13,24.78,28.10(°)
付近に特徴的なピークを示した。
(結晶C)8.06,10.20,10.52,11.01,11.35,11.63,12.92,13.48,14.93,15.95,16.68,16.89,17.33,17.61,18.50,18.72,19.70,19.90,20.49,21.43,21.85,22.16,22.57,23.76,27.96(°)
付近に特徴的なピークを示した。
5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶A~Cを、示差走査熱量分析(DSC)装置(昇温速度5℃/分)で分析した。結晶Aは図7に示すように96、176、184℃付近(±2℃の誤差)、結晶Bは図8に示すように148、183℃付近(±2℃の誤差)、結晶Cは図9に示すように177、183℃付近(±2℃の誤差)に、融解による吸熱ピークを示した。一方、アモルファスは図10に示すように吸熱ピークを有さなかった。
実施例1、実施例2、実施例3にて取得された5-メチルシトシン型架橋型ヌクレオシドアミダイト(R1=ベンズアミド基、R2=メチル基、R3=ジメトキシトリチル基)結晶A~Cと、比較例にて取得されたアモルファスの安定性を、以下に記載する方法にて比較した。
温度:50℃
保管条件:結晶A~C又はアモルファスをガラスバイアル中に20mg入れ密閉保管
サンプリング時間:1、2、3、4、6、20(日)経過後、それぞれの検体をサンプリングし、HPLC分析に供した。
(HPLC条件)
カラム:YMC-Triart C18,150×4.6mmI.D.(YMC社製)
溶出液:80体積%アセトニトリルを含む5mM トリエチルアンモニウムアセテート(pH7.0)
検出法:UV280nmによる検出
Claims (7)
- R1がアシル基で保護されたアミノ基、ジメチルアミノメチレン基で保護されたアミノ基、又はアミノ基であり、R2がメチル基又は水素原子であり、R3がトリチル基、モノメトキシトリチル基、ジメトキシトリチル基又はピキシル基である、請求項1に記載のシトシン型架橋型ヌクレオシドアミダイト結晶。
- R1がベンズアミド基であり、R2がメチル基であり、R3がジメトキシトリチル基である、請求項1又は2に記載のシトシン型架橋型ヌクレオシドアミダイト結晶。
- Cu-Kα線を用いた粉末X線回折の回折角(2θ)として、下記に示す結晶A、結晶B、及び結晶Cの特徴的なピークパターンのうちいずれか1つを有する、請求項1から3のいずれか1項に記載のシトシン型架橋型ヌクレオシドアミダイト結晶。
(結晶A)7.96±0.40,8.94±0.45,9.50±0.48,10.49±0.52,11.00±0.55,11.12±0.56,13.45±0.67,13.82±0.69,16.79±0.84,17.76±0.89,18.22±0.91,19.14±0.96,19.27±0.96,19.84±0.99,20.31±1.02,20.60±1.03,21.38±1.07,22.65±1.13,24.99±1.25,25.33±1.27,26.42±1.32(°)
(結晶B)8.09±0.41,10.28±0.51,10.59±0.53,11.07±0.55,11.38±0.57,12.93±0.65,13.50±0.68,15.01±0.75,16.73±0.84,16.92±0.85,17.43±0.87,17.74±0.89,18.77±0.94,19.71±0.99,20.51±1.03,21.50±1.08,21.74±1.09,22.00±1.10,22.22±1.11,22.72±1.14,23.43±1.17,23.80±1.19,24.13±1.21,24.78±1.24,28.10±1.41(°)
(結晶C)8.06±0.40,10.20±0.51,10.52±0.53,11.01±0.55,11.35±0.57,11.63±0.58,12.92±0.65,13.48±0.67,14.93±0.75,15.95±0.80,16.68±0.83,16.89±0.85,17.33±0.87,17.61±0.88,18.50±0.93,18.72±0.94,19.70±0.99,19.90±1.00,20.49±1.02,21.43±1.07,21.85±1.09,22.16±1.11,22.57±1.13,23.76±1.19,27.96±1.40(°) - シトシン型架橋型ヌクレオシドアミダイトアモルファスをニトリル系溶媒に溶解し、析出する結晶を取得する工程を含む、シトシン型架橋型ヌクレオシドアミダイト結晶の製造方法。
- シトシン型架橋型ヌクレオシドアミダイトアモルファスを易溶性溶媒に溶解後、難溶性溶媒を添加する工程を含む、シトシン型架橋型ヌクレオシドアミダイト結晶の製造方法。
- 前記易溶性溶媒が、アルコール系溶媒、ケトン系溶媒、ハロゲン系溶媒、エステル系溶媒、エーテル系溶媒より選択されるいずれか1種以上の溶媒であり、前記難溶性溶媒が炭化水素系溶媒である、請求項6に記載のシトシン型架橋型ヌクレオシドアミダイト結晶の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237016149A KR20230118076A (ko) | 2020-12-11 | 2021-12-10 | 시토신형 가교형 뉴클레오시드 아미다이트 결정 및 그 제조 방법 |
JP2022568357A JPWO2022124410A1 (ja) | 2020-12-11 | 2021-12-10 | |
CN202180075896.8A CN116472276A (zh) | 2020-12-11 | 2021-12-10 | 胞嘧啶型交联型核苷亚磷酰胺晶体及其制造方法 |
US18/265,880 US20240083935A1 (en) | 2020-12-11 | 2021-12-10 | Cytosine-type bridged nucleoside amidite crystals and method for producing same |
EP21903506.0A EP4265627A1 (en) | 2020-12-11 | 2021-12-10 | Cytosine-type crosslinked nucleoside amidite crystals and method for producing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020205688 | 2020-12-11 | ||
JP2020-205688 | 2020-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022124410A1 true WO2022124410A1 (ja) | 2022-06-16 |
Family
ID=81974587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/045679 WO2022124410A1 (ja) | 2020-12-11 | 2021-12-10 | シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240083935A1 (ja) |
EP (1) | EP4265627A1 (ja) |
JP (1) | JPWO2022124410A1 (ja) |
KR (1) | KR20230118076A (ja) |
CN (1) | CN116472276A (ja) |
WO (1) | WO2022124410A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10304889A (ja) | 1997-03-07 | 1998-11-17 | Takeshi Imanishi | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
JP2002521310A (ja) * | 1997-09-12 | 2002-07-16 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
JP2004536125A (ja) * | 2001-07-12 | 2004-12-02 | サンタリス・ファルマ・アクティーゼルスカブ | Lnaホスホラミダイトの製造法 |
WO2019224172A1 (en) * | 2018-05-25 | 2019-11-28 | Roche Innovation Center Copenhagen A/S | Novel process for making allofuranose from glucofuranose |
WO2020099533A1 (en) * | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
-
2021
- 2021-12-10 US US18/265,880 patent/US20240083935A1/en active Pending
- 2021-12-10 WO PCT/JP2021/045679 patent/WO2022124410A1/ja active Application Filing
- 2021-12-10 JP JP2022568357A patent/JPWO2022124410A1/ja active Pending
- 2021-12-10 KR KR1020237016149A patent/KR20230118076A/ko unknown
- 2021-12-10 CN CN202180075896.8A patent/CN116472276A/zh active Pending
- 2021-12-10 EP EP21903506.0A patent/EP4265627A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10304889A (ja) | 1997-03-07 | 1998-11-17 | Takeshi Imanishi | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
JP2002521310A (ja) * | 1997-09-12 | 2002-07-16 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
JP2004536125A (ja) * | 2001-07-12 | 2004-12-02 | サンタリス・ファルマ・アクティーゼルスカブ | Lnaホスホラミダイトの製造法 |
WO2019224172A1 (en) * | 2018-05-25 | 2019-11-28 | Roche Innovation Center Copenhagen A/S | Novel process for making allofuranose from glucofuranose |
WO2020099533A1 (en) * | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
Non-Patent Citations (9)
Title |
---|
C. RIML ET AL.: "Synthesis of 5-Hydroxymethylcytidine- and 5-Hydroxymethyl-uridine-Modified RNA", SYNTHESIS, vol. 48, 2016, pages 1108 - 1116 |
KAORU : "Recrystallization method and precipitation method", EXPERIMENTAL CHEMISTRY COURSE (CONTINUED) 2 SEPARATION AND PURIFICATION, 25 January 1967 (1967-01-25), pages 159-178, 186 - 187, XP009509740 * |
KOSHKIN, A.A. SINGH, S.K. NIELSEN, P. RAJWANSHI, V.K. KUMAR, R. MELDGAARD, M. OLSEN, C.E. WENGEL, J.: "LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition", TETRAHEDRON, ELSEVIER SIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 14, 2 April 1998 (1998-04-02), AMSTERDAM, NL , pages 3607 - 3630, XP004110505, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(98)00094-5 * |
L. TAKESHITA ET AL.: "Synthesis of Deoxypseudouridine 5'-Triphosphate Bearing the Photoremovable Protecting Group at the N1 Position Capable of Enzymatic Incorporation to DNA", J. ORG. CHEM., vol. 85, 2020, pages 1861 - 1870 |
M. HORIBA ET AL.: "Synthesis of scpBNA-mC, -A, and -G Monomers and Evaluation of the Binding Affinities of scpBNA-Modified Oligonucleotides toward Complementary ssRNA and ssDNA", J. ORG. CHEM., vol. 81, 2016, pages 11000 - 11008, XP055376695, DOI: 10.1021/acs.joc.6b02036 |
NIELSEN POUL, ET AL.: "α-LNA (locked nucleic acid with α-D-configuration): synthesis and selective parallel recognition of RNA", CHEMISTRY-A EUROPEAN JOURNAL, vol. 8, no. 3, 2 February 2002 (2002-02-02), pages 712 - 722, XP055940870, DOI: 10.1002/1521-3765(20020201)8:3<712::AID-CHEM712>3.0.CO;2-0 * |
SORENSEN M D,ET AL: "alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): Synthesis and properties", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 124, no. 10, 13 March 2002 (2002-03-13), pages 2164 - 2176, XP002281373, ISSN: 0002-7863, DOI: 10.1021/ja0168763 * |
T. UEMOTO ET AL.: "Direct and practical synthesis of 2'-O,4'-C-aminomethylene-bridged nucleic acid purine derivatives by transglycosylation", TETRAHEDRON, vol. 73, 2017, pages 1211 - 1218 |
TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630 |
Also Published As
Publication number | Publication date |
---|---|
KR20230118076A (ko) | 2023-08-10 |
US20240083935A1 (en) | 2024-03-14 |
CN116472276A (zh) | 2023-07-21 |
JPWO2022124410A1 (ja) | 2022-06-16 |
EP4265627A1 (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7296882B2 (ja) | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 | |
JP5714490B2 (ja) | Rna合成、リバース方向での合成rnaためのホスホラミダイト、及びrnaオリゴマーの合成のための5’から3’方向に対する結合形成によるオリゴヌクレオチドを調製する方法 | |
US9624258B2 (en) | Polymorph of regadenoson | |
CN110914278B (zh) | 在可见光区能进行光交联的光响应性核苷酸类似物 | |
WO2014068589A2 (en) | Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide | |
WO2022124410A1 (ja) | シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 | |
JP7475056B2 (ja) | 光応答性ヌクレオチドアナログの製造方法 | |
EP1253154B1 (en) | Method for purifying 5'-protected 2'-deoxypurine nucleosides | |
JP4326841B2 (ja) | 保護化2’−デオキシシチジン類の精製法 | |
JP5192807B2 (ja) | シュードウリジン保護体の安定結晶 | |
WO2020256084A1 (ja) | 架橋型ヌクレオシド中間体の結晶及びその製造方法、並びに架橋型ヌクレオシドアミダイトの製造方法 | |
KR100741310B1 (ko) | 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법 | |
JP2019508438A (ja) | 核配列に組み込むための5−(n−保護−トリプタミノカルボキシアミド)−2’−デオキシウリジンホスホロアミダイトの化合物及び合成方法 | |
TWI399381B (zh) | 克拉屈濱(cladribine)的製備方法 | |
WO2022005988A2 (en) | Solid support for synthesizing nucleic acid sequences and methods for making and using | |
JP2009519325A (ja) | 2’、2’−ジフルオロヌクレオシドと中間体の製造プロセス | |
EP2948467A1 (en) | Method for the solid-phase based synthesis of phosphate-bridged nucleoside conjugates | |
JP5105404B2 (ja) | 水素結合性置換基を有する8−置換グアノシン誘導体及びそれを含むオリゴヌクレオチド | |
RU2135512C1 (ru) | Способ получения 3'-азидо- 2', 3'-дидезокситимидина | |
JP3983085B2 (ja) | 5’位保護化2’−デオキシプリンヌクレオシド類の包接化合物の製法 | |
JPH0272191A (ja) | 2′,3′―ジデオキシヌクレオシドの製造方法 | |
JP2000264897A (ja) | 5’−o−トリチルヌクレオシド類の製造法 | |
JP2004131434A (ja) | 5’位保護化プリンヌクレオシド誘導体の単離精製法 | |
WO2005021571A1 (ja) | N4−ベンゾイルシチジン誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21903506 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180075896.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022568357 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18265880 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021903506 Country of ref document: EP Effective date: 20230711 |